Physician profile
Jack D Keller
NPI 1467636605
$4,338.41
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $1,366 · 2021: $2,518 · 2022: $173.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $526.67 | 2019-2022 | |
| Lilly USA, LLC | $522.63 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $413.87 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $338.06 | 2019-2021 | |
| Amarin Pharma, INC. | $298.13 | 2020-2022 | |
| Allergan, INC. | $267.94 | 2019-2020 | |
| Abbvie INC. | $263.58 | 2021 | |
| Amgen INC. | $208.27 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $162.63 | 2019-2020 | |
| Pfizer INC. | $156.43 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $155.85 | 2020-2021 | |
| Eisai INC. | $146.93 | 2021 | |
| Dexcom, INC. | $144.29 | 2021 | |
| Merck Sharp & Dohme LLC | $143.83 | 2019-2021 | |
| Glaxosmithkline, LLC. | $134.88 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.43 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.87 | 2021-2022 | |
| Mylan Specialty L.P. | $41.95 | 2020-2021 | |
| Scilex Pharmaceuticals INC. | $41.06 | 2019 | |
| Sunovion Pharmaceuticals INC. | $38.24 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.42 | 2021 | |
| Sanofi-Aventis U.S. LLC | $35.09 | 2021 | |
| Novartis Pharmaceuticals Corporation | $31.39 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $29.57 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $24.93 | 2020-2021 | |
| Agile Therapeutics, INC. | $17.31 | 2021 | |
| Vistapharm, INC. | $15.16 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Keller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.